|
Dear Immunization Partners,
On April 22, 2023, the Centers for Disease Control and Prevention (CDC) updated their Interim Clinical Considerations for use of COVID-19 Vaccines Currently Authorized in the United States. Since this update, the Michigan Department of Health and Human Services (MDHHS) Division of Immunization has been receiving several emails requesting clarification of the Moderna COVID-19 vaccine dosage for pediatric patients 6 months through 5 years of age who are NOT moderately or severely immunocompromised.
To clarify, the only individuals who will receive the 0.2mL dose from the dark pink cap/yellow label border are those 6 months through 5 years who have received 2 previous doses of Monovalent Moderna COVID-19 vaccine.
Those who are 6 months through 5 years of age who are unvaccinated or who have received 1 previous dose of monovalent Moderna COVID-19 vaccine will receive 0.25mL of the dark blue cap/gray label border (this is the same recommendation as those 6 through 11 years of age).
This authorization was a result of the documentation (evidence) that was provided by the manufacturer to the U.S. Food and Drug Administration (FDA) when they requested to amend the EUA to update the dosing and administration schedule.
Please be sure to follow CDC’s chart in the Interim Clinical Considerations (for reference, please see below Moderna COVID-19 vaccine recommendations for persons aged 6 months through 4 years and aged 5 years who are NOT moderately or severely immunocompromised)
 
|
